Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials

Addiction

Volumn 110, Issue 7, 2015, Pages 1182-1193

  Agboola, Shade A ^a   Coleman, Tim ^a   McNeill, Ann ^b   Leonardi Bee, Jo ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UK CENTRE FOR TOBACCO AND ALCOHOL STUDIES   (United Kingdom)

Author keywords

Abstinence; Addiction; Relapse; Smoking cessation; Varenicline

Indexed keywords

NICOTINE GUM; NICOTINIC AGENT; VARENICLINE;

ADULT; DRUG THERAPY; EPIDEMIOLOGY; HUMAN; META ANALYSIS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SMOKING; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; HUMANS; MIDDLE AGED; NICOTINIC AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; VARENICLINE;

EID: 84931058184     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12941     Document Type: Article

References (39)

1. Cahill K., Stead L., Lancaster T. Nicotine rescptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 2: CD006103.
2. Fagerstrom K., Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat 2008; 4: 353-63.
3. Garrison G., Dugan S. Varenicline: a first line treatment option for smoking cessation. Clin Ther 2009; 31: 463-91.
4. Turner J., Castellano L., Blendy J. Parallel anxiolytic-like effects and upregulation or neuronal nicotinic acetylocholine receptors following chronic nicotine and varenicline. Nicotine Tob Res 2011; 13: 41-6.
5. Taylor M., Leonardi-Bee J., Agboola S., McNeill A., Coleman T. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction 2011; 106: 1819-26.
6. Medioni J., Berlin I., Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach. Addiction 2005; 100: 247-54.
7. Piasecki T., Fiore M., McCarthy D., Baker T. Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction 2002; 97: 1093-108.
8. Cahill K., Stead L., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: 1-119.
9. Hughes J., Keely J., Naud S. Shape of the relapse curve and long term abstinence amongst untreated smokers. Addiction 2004; 99: 29-38.
10. Hughes J., Keely J., Niaura R., Ossip-Klein D., Richmond R., Swan G. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-25.
11. Keely J., Hughes J., Carpenter M. A method to convert prolonged abstinence and point prevalence quit rates. Nicotine Tob Res 2001; 3: 272-3.
12. Velicer W., Prochaska J. A comparison of four self-report smoking cessation outcome measures. Addict Behav 2004; 29: 51-60.
13. Cochrane Tobacco Addiction (CTA) Group. Cochrane Tobacco Addiction Group Glossary: The Cochrane Collaboration, 2010. Web Page. (accessed February 2014)
14. Piasecki T. Relapse to smoking. Clin Psychol Rev 2006; 26: 196-215.
15. Higgins J., Altman D., Gotzsche P., Juni P., Moher D., Oxman A. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: 1-9.
16. Stuart A., Ord J. Kendall's advanced theory of statistics. Distribution Theory, 6th edn. New York: Wiley-Blackwell; 1994.
17. Higgins J., Thompson S. Quantifying heterogeneity in meta-analysis. Stat Med 2002; 21: 1539-58.
18. Swan G. E., McClure J. B., Jack L. M., Zbikowski S. M., Javitz H. S., Catz S. L. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med 2010; 38: 482-90.
19. Aubin H. J., Bobak A., Britton J. R., Oncken C., Billing C., Gong J., et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 1: 1-8.
20. Bolliger C. T., Issa J. S., Posadas-Valay R., Safwat T., Abrue P., Correia E. A., et al. Effects of varenicline in adult smokers: a multinational, randomized, double-blind, placebo controlled study. Clin Ther 2011; 33: 465-77.
21. Gonzales D., Rennard S. T., Nides M., Oncken C., Billing C., Watsky E. J., et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained release bupropion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
22. Jorenby D., Hays T., Rigitti N., Azoulay S., Watsky E., Williams K. Efficacy of varenicline, an α4β2 nicotinic acetylocholine receptor partial agonist, versus placebo or sustained release bupropion for smoking cessation. A randomised controlled trial. JAMA 2006; 296: 56-63.
23. Nakamura M., Oshima A., Fujimoto Y., Maruyama N., Ishibashi T., Reeves K. R. Efficacy and Tolerability of varenicline an α4β2 nicotinic acetylcholine receptor partial agonist in a 12week, randomized, placebo-controlled, dose-response study with 40week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29: 1040-56.
24. Niaura R., Hays T., Jorenby D., Leone F. T., Pappas J. E., Reeves K. R., et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008; 24: 1931-41.
25. Nides M., Oncken C., Gonzales D., Rennard S. T., Watsky E. J., Anziano R., et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch Intern Med 2006; 166: 1561-8.
26. Oncken C., Gonzales D., Nides M., Rennard S. T., Watsky E. J., Billing C., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-7.
27. Rennard S. T., Hughes J., Cinciripini P. M., Kralikova E., Raupach T., Artega C., et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2011; 14: 343-50.
28. Rigotti N. A., Pipe A. L., Benowitz N. L., Arteaga C., Garza D., Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. Circulation 2010; 121: 221-9.
29. Smith B. J., Carson K. V., Brinn M. P., Labiszewski N. A., Peters M. J., Fitridge R., et al. Smoking termination opportunity for in-patients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomized controlled trial for in-patients. Thorax 2013; 68: 485-6.
30. Steinberg M. B., Randall J., Greenhaus S., Schmelzer A. C., Richardson D., Carson J. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addict Behav 2011; 36: 1127-32.
31. Tashkin D. P., Rennard S. T., Hays T., Ma W., Lawrence D., Lee T. C. Effects of varenicline on smoking cessation in patients with mild to moderate COPD-a randomized controlled trial. Chest 2011; 139: 591-9.
32. Tonstad S., Tonnesen P., Hajek P., Williams K. E., Billing C., Reeves K. R. Effect of maintenance therapy with varenicline on smoking cessation. A randomized controlled trial. JAMA 2006; 296: 64-71.
33. Tsai S., Cho H., Cheng H., Kim C., Hsueh K., Billing C., et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29: 1027-39.
34. Tsukahara H., Noda K., Keijiro S. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers. Circ J 2010; 74: 771-8.
35. Wang C., Xiao D., Chan K. P., Pothirat C., Garza D., Davies S. Varenicline for smoking cessation: a placebo-controlled randomized study. Respirology 2009; 14: 384-92.
36. Williams J. M., Anthenelli R. M., Morris C. D., Treadow J., Thompson J. R., Yunis C., et al. A randomized, double blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73: 654-60.
37. Williams K. E., Reeves K. R., Billing C., Pennington A. M., Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007; 23: 793-801.
38. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
39. Hajek P., Stead L., West R., Jarvis M., Hartmann-Boyce J., Lancaster T. Relase prevention interventions for smoking cessation. Cochrane Database Syst Rev 2013; 8: CD003999.